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Background: Hypertrophic cardiomyopathy (HCM) is the leading cause of sudden cardiac death 
(SCD) in children and young adults. Our objective was to develop and validate a SCD risk 
prediction model in pediatric HCM to guide SCD prevention strategies. 
Methods: In an international multi-center observational cohort study, phenotype-positive 
patients with isolated HCM <18 years at diagnosis were eligible. The primary outcome variable 
was the time from diagnosis to a composite of SCD events at 5-year follow-up: SCD, 
resuscitated sudden cardiac arrest (SCA), and aborted SCD, i.e. appropriate shock following 
primary prevention ICD. Competing risk models with cause-specific hazard regression were used 
to identify and quantify clinical and genetic factors associated with SCD. The cause-specific 
regression model was implemented using boosting, and tuned with ten repeated four-fold cross-
validations. The final model was fitted using all data with the tuned hyperparameter value that 
maximizes the c-statistic, and its performance was characterized using c-statistic for competing 
risk models. The final model was validated in an independent external cohort (SHaRe, n=285).  
Results: Overall, 572 patients met eligibility criteria with 2855 patient-years of follow-up. The 
5-year cumulative proportion of SCD events was 9.1% (14 SCD, 25 resuscitated SCA, 14 
aborted SCD). Risk predictors included age at diagnosis, documented non-sustained ventricular 
tachycardia, unexplained syncope, septal diameter z-score, LV posterior wall diameter z-score, 
LA diameter z-score, peak LV outflow tract (LVOT) gradient, and presence of a pathogenic 
variant. Unlike adults, LVOT gradient had an inverse association, and family history of SCD had 
no association with SCD. Clinical and clinical/genetic models were developed to predict 5-year 
freedom from SCD. Both models adequately discriminated patients with and without SCD events 
with a c-statistic of 0.75 and 0.76 respectively and demonstrated good agreement between 
predicted and observed events in the primary and validation cohorts (validation c-statistic 0.71 
and 0.72 respectively).   
Conclusions: Our study provides a validated SCD risk prediction model with over 70% 
prediction accuracy and incorporates risk factors that are unique to pediatric HCM. An 
individualized risk prediction model has the potential to improve the application of clinical 
practice guidelines and shared decision-making for ICD insertion.  
Clinical Trial Registration: URL: https://clinicaltrials.gov Unique Identifier: NCT04036799  
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Clinical Perspective  
 
What is new? 
• Pediatric hypertrophic cardiomyopathy (HCM) patients had a high 5-year cumulative 
sudden cardiac death (SCD) risk of 9.1%. 
• A large international cohort analysis identified a positive association of unexplained 
syncope and non-sustained ventricular tachycardia, a non-linear association of age, septal 
and left ventricular (LV) posterior wall thickness and left atrial diameter, and no 
association of LV outflow tract gradient with SCD risk (inverse association with a 
gradient ≥100 mmHg). 
• An integrated model that incorporated all age-appropriate risk factors provided 
individualized scores for 5-year SCD risk and is the first prediction model to be 
externally validated in an independent cohort with high performance accuracy. 
 
What are the clinical implications? 
• The decision for primary prevention implantable cardioverter defibrillator (ICD) in 
pediatric HCM patients should not be based on a single risk factor but should incorporate 
all age-appropriate, evidence-based risk factors. 
• The PRIMaCY SCD risk prediction model can be implemented within hospital electronic 
health systems as a point of care tool to help guide physicians in shared decision making 











Hypertrophic cardiomyopathy (HCM) is the most common form of cardiomyopathy affecting at 
least 1 in 500 individuals and is a leading cause of sudden cardiac death (SCD) in adolescents 
and young adults.1-3 SCD is related primarily to the occurrence of significant arrhythmias 
including ventricular fibrillation (VF) or sustained ventricular tachycardia (VT).4, 5 Implantable 
cardioverter defibrillators (ICDs) can prevent SCD by detecting and terminating sustained VT or 
VF. They are offered to patients who have survived documented near-death events i.e. secondary 
prevention ICD, or prophylactically in those who have not yet suffered an event but who are 
deemed at high risk for an event i.e. primary prevention ICD. Despite availability of this life-
saving intervention, the lack of precision in predicting SCD risk hampers timely ICDs in at-risk 
individuals resulting in tragic but preventable deaths. Additionally, risk is often overestimated in 
lower risk patients resulting in potentially unwarranted ICD implantation.6-10 This can have 
negative medical, psychological and financial consequences since ICD therapy is associated with 
a 20% complication rate, and 11% inappropriate shock rate in children (higher with epicardial 
ICD placement).8, 11-14 
Published clinical practice guidelines define high risk for SCD by the presence of one or 
more clinical risk factors.4, 15, 16 However, clinical practice recommendations are inconsistently 
and variably applied in practice likely because ICD decision-making is driven by subjective  
perception of risk with considerable variability in risk tolerance amongst practitioners and 
patients, as well as a more conservative uptake due to a higher complication rate of ICDs in 
pediatric compared to adult patients.8, 16, 17 In recent years, the European Society of Cardiology 
(ESC) developed and validated a web-based tool that incorporates evidence-based clinical risk 









but does not apply to children.18-22 This model did not include other potential risk factors like 
genetic etiology of HCM which can influence the risk of SCD.15, 23, 24 In addition, studies have 
shown that the ESC 2014 risk prediction model had a lower sensitivity in high-risk populations. 
As a result, the ESC 2014 model frequently mis-identified patients who experienced a SCD 
event as low risk.20, 25-27 A recent study from the United Kingdom (UK) reported on the 
performance of a SCD risk prediction model for pediatric HCM developed using 5 pre-selected 
clinical variables with a c-statistic of 0.69; but this model has not been externally validated.28 
The lack of evidence-based decision support for SCD risk prediction in childhood HCM has been 
identified as an important practice gap. 
 The purpose of our study was to develop and validate a risk prediction model for SCD in 
pediatric HCM using evidence-based risk factors in order to assist physicians and patients in 
shared decision making for primary prevention ICD implantation.  
 
Methods 
The data that support the findings of this study are available from the corresponding author upon 
reasonable request. 
Study cohort and participating centers 
This was a multicenter retrospective observational cohort study of pediatric patients with 
clinically diagnosed childhood onset HCM. Eligibility criteria included clinical diagnosis of 
HCM, left ventricular (LV) posterior wall or septal thickness z-score ≥ 2 29, 30, age less than 18 
years at the time of diagnosis, absence of a SCD event prior to diagnosis, and at least one follow-
up assessment after diagnosis. Genotype-positive subjects who did not have echocardiographic 









i.e. clinical syndromes like RASopathies, endocrine, metabolic, mitochondrial or neuromuscular 
disorders, hypertension, and structural heart defects were excluded. Age at diagnosis was defined 
as the age at echocardiogram at which the diagnosis of HCM was made. All centers used the 
same echocardiographic criteria for the diagnosis of hypertrophy. 
The primary cohort included patients from 11 sites participating in the PRecIsion 
Medicine for CardiomyopathY (PRIMaCY) study, an international registry of pediatric HCM 
patients launched in 2017. These included 4 Canadian, 6 United States and 1 Australian site. For 
model validation in an independent cohort, we used data from patients with childhood onset 
HCM from the Sarcomeric Human Cardiomyopathy Registry (SHaRe), a registry of 15 
international centers capturing longitudinal clinical data on de-identified patients with HCM.23 
For the 4 sites that contributed data to both registries, any overlapping patients were excluded 
from the validation cohort. Clinical, genetic and outcomes data were collected from the medical 
records in all eligible patients from the time of diagnosis to last follow-up. Echocardiographic 
data was collected at initial diagnosis and at last follow-up. For patients with major cardiac 
events (death, transplant, SCD), data was captured prior to the event. Echocardiographic data 
was collected from clinical reports and where feasible, missing data was collected through a re-
review of the echocardiograms at local sites by the research team. SCD events were reviewed by 
site investigators to confirm the cause of death. The research protocol was approved by the 
institutional research ethics boards at all sites and waiver of consent was obtained for this 
retrospective study. All patient data was de-identified for data sharing and analyses. The 
corresponding author had full access to all the data in the study and takes responsibility for its 










Selection of predictor variables 
To generate a risk prediction model, candidate risk factors based on the American College of 
Cardiology Foundation/American Heart Association (ACCF/AHA) published clinical practice 
guidelines were assessed.4 Echocardiographic measurements of wall thickness and chamber sizes 
were converted to z scores using the Boston z-score calculator.29, 30 The risk factors included age 
at diagnosis, family history of SCD, history of recent unexplained syncope within 6 months prior 
to diagnosis, documented non-sustained VT (defined as ≥3 beats at ≥120 bpm on ambulatory 
electrocardiogram (ECG), interventricular septal diameter (IVSD) z-score, LV posterior wall 
diameter (LVPWD) z-score, left atrial (LA) diameter z-score, and peak resting LV outflow tract 
(LVOT) gradient on echocardiography. Genetic results from clinical testing were captured from 
medical records, and through research sequencing in a subset of patients. Data included affected 
gene, and variant pathogenicity i.e. pathogenic/likely pathogenic, variant of uncertain 
significance or benign.31 Variant classification was reconfirmed using American College of 
Medical Genetics criteria at the core site. Patients harboring pathogenic/likely pathogenic 
variants in cardiomyopathy genes were considered genotype-positive (Supplementary Table I). 
Ethnicity information was only available in 102 patients and therefore was not included in the 
analysis. 
Statistical Analysis 
All statistical analyses were performed using R v3.4.1 with survival, multiple imputation by 
chained equations (MICE), mboost, riskRegression and mlr packages. Clinical characteristics 
were summarized using descriptive statistics. Continuous variables were summarized using 
median and interquartile range (IQR) while categorical variables were summarized using 









follow-up defined as a composite outcome of SCD, resuscitated sudden cardiac arrest (SCA) 
(including sustained VT/VF), and aborted SCD events i.e. appropriate shock in a patient with a 
primary prevention ICD. Event-free survival was estimated using the Kaplan-Meier method as 
was the cumulative proportion of SCD events over time.  
Model development and performance assessment 
General modeling approach 
To generate a risk prediction model, the relative contribution of the clinical and genetic 
predictors was quantified using a competing risk model for SCD events with non-SCD death as 
the competing risk. This analysis was implemented using cause-specific regression. To ensure 
that the quantification was pertinent to the clinical context, patients were administratively 
censored at 5 years from first evaluation. Two models were considered – a clinical only model, 
and a clinical/genetic model that included genotype status of the patient. Patients harboring a 
pathogenic/likely pathogenic causal variant on genetic testing i.e. genotype-positive patients, 
were compared to patients without a causal variant on testing. We applied a model-boosting 
algorithm to the cause-specific hazard regression to identify and quantify the association between 
the candidate risk factors and the composite outcome. For continuous risk factors, the 
associations were modeled without the assumption of linearity using penalized b-splines. The 
estimated non-linear associations were summarized graphically. Upon the fitting of the two 
boosted models, we then obtained the linear predictors and baseline hazard for the SCD events. 
This cause-specific hazard regression implementation for competing risk data has been 
previously described.32 
Model tuning 









hyperparameter of the boosting model. In this exercise, we considered a small learning rate (step 
size) of 0.01 and a large number of steps. Within each cross-validation iteration, we imputed the 
missing values using MICE before training the model. This scheme of nested imputation was 
demonstrated in a similar prognostic study setting.33,34 The plausibility of missing at random 
assumed in the imputation depends on the candidate risk factors. As long as the candidate risk 
factors considered in the study are comprehensive, as in our study, this assumption is reasonable. 
Next we applied the trained model and calculated the c-statistic on the cross-validation data for 
each step. The ‘optimal’ number of steps (i.e. the value of the boosting model hyperparameter) 
was the one that maximized the c-statistic averaged over all cross-validation iterations. The final 
model was then fitted using all data with the ‘optimal’ hyperparameter value estimated in the 
model tuning exercise. Given the competing risk data, separate cause-specific hazard regression 
models were fitted and tuned – one for SCD events and the other for non-SCD deaths. Of note, 
due to a small number of patients with non-SCD deaths, we only applied three-fold cross-
validation to identify and quantify the risk factors associated with non-SCD deaths. 
Model performance 
Upon model fitting, both prognostic index and the 5-year cumulative proportion of SCD events 
was quantified for each patient. The discriminatory power of the final model was quantified 
using the c-statistic for competing risk models.35 Model calibration was assessed by stratifying 
patients into three risk groups based on tertiles of the predicted 5-year probability of a SCD event 
and by creating a calibration curve to show the relationship between the observed and predicted 
5-year probability of events. 
Model validation 









285 eligible patients from SHaRe after excluding 321 patients that overlapped with the discovery 
cohort. Harrell’s c-statistic was calculated, and calibration curves were constructed using 
quantiles of predicted risk as described above. 
 
Results 
The final derivation cohort consisted of 572 eligible phenotype-positive HCM patients diagnosed 
between 1987-2018. This included 535 unrelated probands and 37 affected siblings of the 
probands. The distribution of cases by center and by age at diagnosis is shown in Supplemental 
Figure I. Baseline clinical and echocardiographic characteristics at diagnosis for the primary and 
validation cohorts are displayed in Table 1. 368 (64%) patients had asymmetric septal 
hypertrophy. There were no cases of apical hypertrophy. The median age at diagnosis was 9.8 
years [IQR 2.1-13.9]. The median follow-up duration was 3.9 [1.5-6.7] years (duration to either 
death or the last known date alive). 336 of 565 (59%) patients received beta-blockers during 
follow-up; medication data was not available in 7 patients. Of the 311 (54%) subjects who had 
genetic testing reported, 160 (28%) were identified as carrying at least one causal 
pathogenic/likely pathogenic variant. The affected genes in the primary and validation cohorts 
are shown in Supplemental Table I.  
Time to SCD events 
Over the 2,855 total patient years of follow-up, 53 patients experienced a SCD event including 
14 sudden deaths, 25 resuscitated SCA, and 14 appropriate shocks in patients with primary 
prevention ICDs. No patients in the cohort were phenotype-negative at the time of a SCD event. 
Of the102 patients who received an ICD for primary prevention, 14 experienced an appropriate 









years follow-up after ICD, and 7 experienced an inappropriate shock. Inappropriate shock 
information was unavailable in 19 patients. (Supplemental Figure II). Supplemental Figure 
III shows the indications for primary prevention ICD implantation with 63% patients receiving 
an ICD for a single indication. The median time to a SCD event from diagnosis was 2.2 years 
[IQR 0.9-5.2], and median age at an SCD event was 14.5 years [IQR 12.4 – 17.1]. The 
cumulative proportion of SCD events at 1-year follow-up was 2.8% [95% CI = 1.4%, 4.2%], and 
at 5 years was 9.1% [6.3%, 11.9%] (Figure 1a).  
Clinical predictors of time to SCD events 
The final clinical model included age at diagnosis, IVSD z-score, LVPWD z-score, LA diameter 
z-score, peak LV outflow tract gradient, non-sustained VT, and history of syncope. LA diameter 
z-score was imputed in 21% patients in the overall cohort, and LVOT gradient in 29% patients in 
the overall cohort. Of the 53 patients who experienced a SCD event, LA diameter was imputed in 
13% and LVOT gradient in 17% patients. Our analysis suggested that prior history of non-
sustained VT increased the likelihood of experiencing SCD events by 2.8 fold (HR [95% CI] 
=2.87 [1.00, 6.57]), and prior history of syncope increased the likelihood of experiencing SCD 
events by 7.4 fold (HR [95% CI] = 7.40 [1.21, 32.81]) (Table 2). A family history of SCD was 
not considered an important predictor either in the overall cohort or the subset with familial 
HCM. Figure 2 shows the regression-adjusted association of the continuous risk factors with the 
composite outcome. Each panel summarizes the non-linear association between a predictor and 
the SCD event. SCD risk increased with increased age at diagnosis, IVSD z-score, LVPWD z-
score, and LA diameter z-score. However, this positive correlation between IVSD and LVPWD 
z-scores plateaued at a z-score >20. In contrast, the risk associated with peak resting LVOT 









with SCD risk as the gradient increased further. For example, an increase in peak LV outflow 
tract gradient from 100 to 120 mmHg reduced the SCD risk by approximately 10%. There was 
no difference in the cumulative proportion of SCD events in patients with and without beta-
blocker use during follow-up (p=0.138) (data not shown). To further clarify the association with 
age, we compared outcomes in patients diagnosed before 5 years of age versus later 
(Supplemental Table II). A third of patients were diagnosed before 5 years of age. They had a 
higher frequency of non-SCD deaths and transplant compared to those diagnosed later and these 
non-SCD events occurred at a median age of <1 year. In contrast, early onset HCM cases had an 
overall lower frequency of SCD events compared to those diagnosed later but the median age at 
SCD events was not different suggesting that the penetrance of SCD remains highest in 
adolescent and teenage years regardless of age at diagnosis. The overall lower frequency of SCD 
in early onset cases may also be related in part to the higher non-SCD mortality and transplant in 
early life. There were no sex-related differences in the risk for SCD events.  
Performance of the clinical prediction model 
The final clinical model was applied to the full cohort. The c-statistic was 0.75 indicating a good 
discriminatory power. Subjects were stratified by tertile of predicted risk and the cumulative 
proportion of SCD-events over time was plotted for each tertile (Figure 2f). The difference in 
cumulative proportion of SCD-events across strata of predicted risk was significant (p<0.001). 
Calibration (the agreement between the magnitude of predicted risk vs. observed risk) was 
assessed by stratifying predicted risk into tertiles and plotting the observed cumulative 
proportion of SCD-events over time against the mean predicted risk for that tertile. This showed 
that subjects with predicted risk in the highest tertile had the highest observed cumulative 









lowest observed cumulative proportion of SCD events. Figure 2g of the calibration curve shows 
good agreement between predicted and observed 5-year cumulative proportion of SCD-events 
for each tertile of predicted risk (Table 3).  
Clinical and genetic predictors of time to SCD events 
The first clinical/genetic model was generated using all clinical predictors above along with 
genotype-positive status. Similar to the clinical model, SCD risk was higher with prior history of 
non-sustained VT (HR [95% CI] = 2.58 [1.00, 6.17]), and prior history of syncope (HR [95% CI] 
= 7.23 [1.09, 33.57]). In addition, the presence of a pathogenic/likely pathogenic variant (i.e. 
being genotype-positive) elevated the likelihood of experiencing SCD events (HR [95% CI] = 
1.32 [1.00, 2.12]) compared to the confirmed absence of a pathogenic variant on genetic testing 
(Table 2). For continuous risk factors, Figure 3 shows the regression-adjusted effects of the 
predictors on the primary outcome with a similar relationship as described in the clinical model. 
Performance of the combined clinical/genetic model 
The final clinical/genetic model was applied to the full cohort to generate a cumulative 
proportion curve for 5-year incidence of SCD events. This showed the ability of the risk 
prediction model to discriminate between three tertiles of SCD risk similar to the clinical model 
(p<0.001) (Figure 3f). Figure 3g shows the calibration curve for the three risk tertiles with good 
agreement between predicted and observed SCD event-free survival with an overall c-statistic of 
0.762 which was comparable to the clinical model (Table 3).  
Other models considered 
Since gene involved can influence risk of SCD, we also explored the association of a 
pathogenic/likely pathogenic variant in MYH7, MYBPC3, or other HCM-associated genes i.e. 









pathogenic/likely pathogenic variant in MYBPC3 was associated with a higher risk of SCD 
events but the increase in risk was modest i.e. HR 1.022 [1.00, 1.78]. The c-statistic of this model 
was 0.726, which was lower than that of the first genetic model. Therefore, this model was not 
considered for further validation. The study was not powered to examine the effect of variant 
burden on SCD risk since only 2.8% patients harbored multiple pathogenic variants. 
External validation 
For independent validation of the risk prediction models, we analyzed 285 phenotype-positive 
childhood onset HCM patients from SHaRe. There were minor differences in clinical 
characteristics between the SHaRe and the primary cohorts. The SHaRe patients were older at 
diagnosis, and the racial distribution was 89.6% Caucasians, 4.5% Asian, and 5.2% Black (Table 
1). A higher proportion were genotype-positive, a lower proportion were familial, a higher 
proportion had non-sustained VT, and had higher LA diameter z-scores at baseline. The type of 
SCD events are shown in Supplemental Figure IV. The cumulative proportion of SCD events at 
1-year follow-up was 2.3% [0.5%, 4.1%], and at 5 years was 6.8% [3.2%, 10.3%] with a total of 
22 SCD events over a median follow-up of 3.3 [1.3-7.0] years (Figure 1b). The incidence of 
SCD events was not significantly different from the discovery cohort (p=0.57). Patients in the 
replication cohort were scored using both risk prediction models and performance of each model 
in the validation cohort was assessed. The c-statistic was 0.707 for the clinical model, and 0.724 
for the clinical/genetic model with acceptable agreement between the predicted and observed 5-











The incidence of sudden cardiac death in pediatric HCM is significantly higher than in adults.28 
The 5-year risk of a SCD event in our study was 9.1%. However, only 25% received an ICD that 
was able to abort the event. The remaining patients either died without an ICD or received an 
ICD only after experiencing the event. In addition, of the 102 patients in the cohort who received 
a primary prevention ICD, 86% did not receive an appropriate shock including many who had a 
5-year follow-up. This is comparable to adult studies and highlights a major gap in knowledge on 
how to risk stratify for sudden death in the pediatric population.36, 14, 37 The practice guidelines to 
date have relied on adult markers for risk stratifying children and adolescents.4 Using data from a 
multi-center consortium of pediatric HCM centers, we found important differences in risk factors 
between children and adults. Using age-specific risk factors, we developed and validated a 
pediatric SCD risk prediction model that can bridge this gap in knowledge and provide the 
evidence needed by clinicians to assist in decision making for SCD prevention. Currently, only 1 
in 9 prophylactic ICDs are appropriate implantations.38 The use of a prediction tool has the 
potential to increase appropriate ICD implantation while reducing unwanted ICD implantation in 
a vulnerable population that is at higher risk of ICD complications due to their small size and 
physiological differences from adults. 
To develop this model, we employed an evidence-based approach to determine whether 
the conventional risk factors for SCD identified mostly through adult studies apply to children. 
Our analysis confirmed the positive association of age, history of syncope, non-sustained VT, 
LV wall thickness and LA diameter with SCD risk but also revealed some important differences 
between pediatric and adult risk factors. For example, while there was a linear relationship 









suggesting that unlike adults, there was no clear septal z-score threshold that conferred an 
independent risk of SCD. Also, there was no significant association between peak resting LVOT 
gradient with SCD, and there was an inverse association with SCD at very high gradients. This 
was likely not related to medication use since SCD event frequency was not different by beta-
blocker use. It is not clear if this could be related to a possible protective effect of septal 
myectomy in patients with high gradients.9, 39 The finding of a positive association of age with 
SCD risk is consistent with the known higher penetrance of SCD in adolescents and teenagers.7 
The overall lower frequency of SCD in early onset cases may also be related in part to a lower 
survival into teenage years due to a higher non-SCD mortality and transplant in early life. The 
difference in outcomes is unlikely to be related to the presence of non-sarcomeric gene variants 
in younger patients (all of whom had isolated HCM at the time of diagnosis and follow-up) since 
non-sarcomeric gene variants accounted for less than 3% of early onset cases. In fact, our 
previous work has shown that sarcomeric genotype itself can influence disease onset and severity 
with the affected sarcomeric gene, variant burden and de novo status associated with earlier 
onset HCM and lower freedom from not just SCD but also need for myectomy, transplant or 
death.40 
 We noted that a family history of SCD did not emerge as a significant risk factor which 
may be so for several reasons including the often sporadic occurrence of childhood HCM, a 
higher likelihood that SCD events may not have manifested yet in young adult relatives of child 
probands, and the limitation in tracking all family SCD events in a retrospective study design. 
Further, family history may be protective as it prompts screening, early diagnosis and timely 









between family history of SCD and LVOT gradient with SCD risk in childhood HCM is 
consistent with other recently published reports.7, 41-43 
Prior studies have reported that patients carrying at least one pathogenic/likely 
pathogenic variant were more likely to experience earlier disease onset and worse patient 
outcomes.10, 23, 24, 40, 44, 45 This aligns with our finding that genotype-positive individuals had a 
1.3-fold higher risk of experiencing a SCD event when compared to individuals who were 
genotype-negative on genetic testing after accounting for all clinical risk factors. In a first 
attempt to incorporate genetic risk into the prediction model, we observed only a modest 
difference in prediction accuracy between the clinical and combined models. The failure to see a 
larger difference may be related to the limited uptake of genetic testing whereby only 54% 
patients had undergone genetic testing with less than a third being genotype positive. We also 
explored the effect of incorporating affected gene and variant burden into the model but were 
likely underpowered to identify meaningful genotype-specific differences in SCD risk. Larger 
studies are needed to analyze and incorporate genotype-specific differences in risk predictions. 
Finally, our model provided a good prediction accuracy with a c-statistic of 0.75 which 
was higher when compared to a recent study in a UK cohort where the c-statistic was 0.69 in the 
training set with no external validation.28 The UK study included 5 pre-selected risk factors that 
were not re-evaluated prior to inclusion in the model. Their model did not include age at 
diagnosis, and did not differentiate between IVSD and LVPWD z-scores as independent 
predictors of SCD risk but instead used maximal LV wall thickness in any segment. We re-
evaluated all potential risk factors to ensure that all evidence-based risk factors were included 
and the non-linear relationship of the risk factors with SCD risk was incorporated into the model 









clinical/genetic models using an independent cohort. The predictive accuracy of both models 
remained higher than 0.7 which is comparable in performance to the adult SCD risk calculator in 
clinical use.18 The decrease in c-statistic in the validation cohort may have been related to a non-
significantly lower SCD event rate due to a potential survivor bias since the SHaRe validation 
cohort was comprised predominantly of adult age survivors of childhood onset HCM.  
Clinical significance 
There is important potential for our findings to assist in clinical decision-making to prevent one 
of the most tragic outcomes of pediatric HCM. Our study reports the only independently 
validated model for SCD risk prediction in pediatric HCM, and the only study that provides 
evidence from a large ethnically and geographically relevant North American pediatric cohort. 
Our findings reinforce that most SCD risk factors are not binary and that, in children, the 
decision for ICD should not be made on the basis of a single risk factor especially given the 
higher ICD complication rates in this age group. The model ensures that all validated risk factors 
are considered in the decision making process using an unbiased approach.46 The algorithm we 
have developed not only encapsulates practice recommendations but also provides an 
individualized estimate of 5-year sudden death risk that can be used in ICD shared decision 
making between patient and provider as opposed to a binary classification of high versus low 
risk. The ACC/AHA guidelines include the following Class I recommendation, highlighting the 
emphasis on shared decision making for ICD between patients and providers: “The decision to 
place an ICD in patients with HCM should include application of individual clinical judgment, 
as well as a thorough discussion of the strength of evidence, benefits and risks to allow the 
informed patient’s active participation in decision making”.4 Ultimately, this model has the 









individualized risk prediction, and improve clinical outcomes through appropriate ICD use in 
high-risk patients. 
Limitations 
(i) The study has limitations inherent to any retrospective analysis i.e. missing data, survivor 
bias, and lower uptake of genetic testing in the earlier era. Missing echocardiographic data was 
addressed through a re-review of echocardiograms where available and through imputation 
where this was not possible. We deliberately did not perform an echocardiographic core 
laboratory analysis since a real world, point of care tool has to rely on locally acquired data. We 
did however standardize the calculations for z-score measurements. (ii) Our study did not include 
emerging risk factors like late gadolinium enhancement on cardiac MRI due to challenges related 
to low yield of late gadolinium enhancement in children, lack of a clear definition for an 
abnormal cut-off especially in children, variability in cardiac MRI use across centers, and the 
inability to perform this test in younger children without sedation that limits universal clinical 
use at this time. Atypical ventricular phenotypes such as apical aneurysm formation which are 
rare in pediatric HCM were also not included as risk factors. (iii) While some patients harbored 
variants in non-sarcomeric genes like RASopathy-associated genes, we confirmed that patients 
were non-syndromic at the time of clinical ascertainment and did not have a phenotype 
consistent with a syndromic, metabolic or neuromuscular phenotype. (iv) We recognize that 
some appropriate ICD discharges may have been for self-terminating VT/VF which can 
overestimate SCD. Anti-tachycardia pacing events were also not captured. (v) Despite an 
acceptable predictive accuracy of our model at present, we recognize that childhood and 









expression. Future iterations of the model will need to be dynamic and incorporate the trajectory 
of phenotypic change in HCM with time to further improve prediction accuracy. 
Conclusions 
The independently validated PRIMaCY model has over 70% accuracy for SCD risk prediction in 
pediatric HCM. We anticipate that clinical uptake of this model of risk prediction will improve 
the application of clinical practice guidelines, facilitate shared decision making around ICD 
implantation through individualized risk prediction, and improve clinical outcomes through 
appropriate ICD use in high risk pediatric patients while avoiding ICDs in low risk patients. An 
important future goal will be to incorporate this model into hospital electronic health systems as 
a point of care tool for physicians and to assess the implementation effectiveness of this 
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Age at first evaluation (years) 572 9.8 (2.1 – 13.9) 285 13.8 (8.3 – 16.2) <0.001 
Sex (Male) 572 394 (68.9%) 285 199 (69.8%) 0.81 
Genetic testing done 572 311 (54.4%) 285 166 (58.2%) 0.315 
Genetic testing results 311  166  0.024 
Positive  160 (51.4%) 
 
108 (65.0%)  
Inconclusive  66 (21.2%) 
 
27 (16.3%)  
Negative  85 (27.3%) 
 
31 (18.7%)  
Family history of HCM 550 264 (48.0%) 285 102 (35.8%) <0.001 
Family history of SCD 572 105 (18.4%) 206 29 (14.1%) 0.196 
Documented non-sustained VT 572 18 (3.1%) 88 7 (8%) 0.037 
History of unexplained syncope 572 17 (3.0%) 285 6 (2.1%) 0.51 
Received beta blocker 565 336 (59.1%) 284 127 (44.7%) <0.001 
Echocardiographic features at diagnosis   N Statistic  
IVSD z-score 572 9.5 (5.0 – 16.8) 283 9.4 (4.7 – 16.7) 0.66 
LVPWD z-score 566 2.4 (0.3 – 5.0) 269 2.4 (0.6 – 4.9) 0.43 
LA diameter z-score 453 1.1 (0.1 – 2.1) 190 1.4 (0.3 – 2.5) 0.035 
Peak resting LVOT gradient (mm Hg) 401 13 (0.0 – 46.0) 90 10 (7 – 18) 0.81 
LVOT obstructed (qualitative) 121 19 (16%) 175 40 (23%) 0.141 
Survival outcomes   N Statistic  
SCD events 572 53 (9.3%) 285 22 (7.7%) <0.001 
SCD 572 14 (2.4%) 285 8 (2.8%)  
Resuscitated SCA 572 25 (4.4%) 285 9 (3.2%)  
Appropriate shock with prophylactic ICD 572 14* (2.4%) 285 5 (1.8%)  
Incidence rate†   N Statistic  
Years from diagnosis 572 3.9 (1.5, 6.7) 285 3.9 (1.6 – 7.4)  
Patient-years of follow-up 572 2855 285 1400  
Outcomes      
Event-free 572 17.9 285 18.3  
SCD event 572 1.9 285 1.6  
Non SCD death 572 3.2 285 0.5  
* Continuous variables were summarized using median and IQR; categorical variables were summarized using frequencies and 
proportions 
† Incidence rate = Events per 100 patient-years of follow-up 
PRIMaCY, Precision Medicine for Cardiomyopathy; SHaRe, Sarcomeric Human Cardiomyopathy Registry; HCM, 
hypertrophic cardiomyopathy; SCD, sudden cardiac death; VT, ventricular tachycardia; IVSD, inter-ventricular septal diameter; 
LVPWD, left ventricular posterior wall diameter; LA, left atrial; LV, left ventricle; LVOT, left ventricular outflow tract; SCD, 










Table 2. Categorical predictors of 5-year sudden cardiac death risk 
 
Clinical model Hazard ratios [95% CI] 
Prior history of non-sustained VT 2.87 [1.00, 6.57] 
Prior history of syncope   7.40 [1.21, 32.81] 
Clinical/genetic model   
Prior history of non-sustained VT 2.58 [1.00, 6.17] 
Prior history of syncope   7.23 [1.09, 33.57] 
Pathogenic variant in any gene (reference: confirmed absence of variant) 1.32 [1.00, 2.12] 











Table 3. Observed versus model-predicted 5-year freedom from sudden cardiac death (n=572) 
Risk group categories Risk tertile Average 
predicted risk 
Observed risk [95% CI] c-statistic
Clinical model 
low risk < 4.7% 3.4% 2.8% [1.1%, 7.6%] 0.750 
medium risk 4.7% - 8.3% 6.3% 7.2% [3.9%, 13.4%] 
 
high risk > 8.3% 20.0% 18.5% [12.7%, 26.9%] 
Clinical + genetic model 
low risk < 4.7% 3.3% 1.9% [0.6%, 5.9%] 0.762 
medium risk 4.7% - 8.3% 6.2% 7.6% [4.1%, 14.1%] 
 
high risk > 8.3% 20.0% 18.8% [13.1%, 27.1%] 









Figure 1. Cumulative proportion of SCD events estimated using competing risk models in 
PRIMaCY and SHaRe cohorts. PRIMaCY cohort (n=572): The cumulative proportion [95% 
CI] of SCD events in pediatric HCM patients at 1-year follow-up was 2.8% [1.4%, 4.2%], at 5
years was 9.1% [6.3%, 11.9%], and at 10 years was 15.0% [10.0%, 19.7%]. The cumulative 
proportion of death from other causes at 1-year follow-up was 0.9% [0.1%, 1.8%], at 5 years was 
1.8% [0.6%, 3.0%], and at 10 years was 1.8% [0.6%, 3.0%]. b. SHaRE cohort (n=285): The 
cumulative proportion [95% CI] of SCD events at 1-year follow-up was 2.3% [0.5%, 4.1%], at 5 
years was 6.8% [3.2%, 10.3%], and at 10 years was 13.7% [6.5%, 20.4%]. The cumulative 
proportion of death from other causes at 1-year follow-up was 0.7% [0.0%, 1.7%], at 5 years was 
2.1% [0.2%, 3.9%], and at 10 years was 4.5% [0.6%, 8.2%]. PRIMaCY, Precision Medicine for 
Cardiomyopathy Study; SHaRe, Sarcomeric Human Cardiomyopathy Registry; SCD, sudden 
cardiac death; HCM, hypertrophic cardiomyopathy 
Figure 2. Regression-adjusted effects of continuous co-variates and clinical SCD risk 
prediction model performance (n=572). (a-e) The top of each figure shows the observed 
values of the continuous risk predictor among pediatric HCM patients in the training cohort who 
experienced the composite SCD outcome, the bottom shows the observed values of the predictor 
among those who did not experience the composite SCD outcome. SCD risk increased with a) 
age at diagnosis; b) increase in IVSD z-score; c) LVPWD z-score; and d) LA diameter z-score; 
e) The risk associated with peak resting LVOT gradient remained flat when the gradient was








proportion of SCD-events stratified by tertiles of risk predicted by the clinical only model i.e. 
predicted risk below 4.7%, 4.7%-8.3%, and above 8.3%; g) The calibration curve for the clinical 
model applied to the training cohort shows the predicted versus the observed five-year risk of the 
composite SCD outcome. The prediction accuracy i.e. c-statistic of the model was 0.75. The 
dashed line, the 45° line through 0, represents a perfectly calibrated model between the observed 
and the predicted 5-year survival probabilities. 
HCM, hypertrophic cardiomyopathy; SCD, sudden cardiac death; IVSD, inter-ventricular septal 
diameter; LVPWD, left ventricular posterior wall diameter; LA, left atrium; LVOT, LV outflow 
tract 
Figure 3. Regression-adjusted effects of continuous covariates and clinical/genetic SCD risk 
prediction model performance (n=572). (a-e) The top of each figure shows the observed 
values of the continuous risk predictor among pediatric HCM patients in the training cohort who 
experienced the composite SCD outcome, the bottom shows the observed values of the predictor 
among those who did not experience the composite SCD outcome. SCD risk increased with a) 
age at first evaluation; b) increase in IVSD z-score; c) LVPWD z-score; and d) LA diameter z-
score; e) The risk associated with peak resting LV outflow tract gradient remained flat when the 
gradient was ≤100 mmHg and decreased as the gradient increased above 100 mmHg; f) 
Cumulative proportion of SCD-events stratified by tertiles of risk predicted by the 
clinical/genetic model i.e. predicted risk below 4.7%, 4.7%-8.3%, and above 8.3%; g) The 
calibration curve for the clinical/genetic model applied to the training cohort shows the predicted 









statistic of the model was 0.762. The dashed line, the 45° line through 0, represents a perfectly 
calibrated model between the observed and the predicted 5-year survival probabilities. 
HCM, hypertrophic cardiomyopathy; SCD, sudden cardiac death; IVSD, inter-ventricular septal 
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